Blood Res.  2020 Jul;55(S1):S54-S57. 10.5045/br.2020.S009.

AL amyloidosis: advances in diagnosis and management

• Koh Y

• KMID: 2504743
• DOI: http://doi.org/10.5045/br.2020.S009

Abstract

Light chain (AL) amyloidosis is a disease in which malignant plasma cell clones affect multiple organs including the heart and kidney. The mechanism for organ function deterioration in AL amyloidosis differs from multiple myeloma. Thus, not all agents used to treat multiple myeloma shows similar efficacy in AL amyloidosis. In AL amyloidosis, both hematologic and organ responses after treatment are important to improve the clinical outcome. Especially, improving heart function is one of the key aspects in the treatment of AL amyloidosis. With recent advances in the understanding of the pathophysiologic mechanism of AL amyloidosis, novel treatment methods are under active trial. In this article, I have reviewed the advances in pathophysiology, diagnosis, risk stratification, and treatment of AL amyloidosis.

Keyword

AL amyloidosis; SAP; Pathophysiology; Treatment

Figure

• 

  Fig. 1 Pathophysiologic mechanism of AL amyloidosis (Merlini et al. 2018).

Reference

1. Kyle RA, Linos A, Beard CM, et al. 1992; Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 79:1817–22. DOI: 10.1182/blood.V79.7.1817.1817. PMID: 1558973.

2. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. 2018; Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2:1046–53. DOI: 10.1182/bloodadvances.2018016402. PMID: 29748430. PMCID: PMC5965052.

3. da Silva Filho MI, Försti A, Weinhold N, et al. 2017; Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia. 31:1735–42. DOI: 10.1038/leu.2016.387. PMID: 28025584.

4. Merlini G, Dispenzieri A, Sanchorawala V, et al. 2018; Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 4:38. DOI: 10.1038/s41572-018-0034-3. PMID: 30361521.

5. Hipp MS, Park SH, Hartl FU. 2014; Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol. 24:506–14. DOI: 10.1016/j.tcb.2014.05.003. PMID: 24946960.

6. Morgan GJ, Kelly JW. 2016; The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains. J Mol Biol. 428:4280–97. DOI: 10.1016/j.jmb.2016.08.021. PMID: 27569045. PMCID: PMC5065776.

7. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. 1979; Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 38:284–93. PMID: 118839. PMCID: PMC1537850.

8. Marin-Argany M, Lin Y, Misra P, et al. 2016; Cell damage in light-chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding. J Biol Chem. 291:19813–25. DOI: 10.1074/jbc.M116.736736. PMID: 27462073. PMCID: PMC5025671.

9. Imperlini E, Gnecchi M, Rognoni P, et al. 2017; Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep. 7:15661. DOI: 10.1038/s41598-017-15424-3. PMID: 29142197. PMCID: PMC5688098.

10. Kumar S, Dispenzieri A, Lacy MQ, et al. 2012; Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 30:989–95. DOI: 10.1200/JCO.2011.38.5724. PMID: 22331953. PMCID: PMC3675680.

11. Bhatti S, Watts E, Syed F, et al. 2016; Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 17:970–7. DOI: 10.1093/ehjci/jew101. PMID: 27225804.

12. Vaxman I, Dispenzieri A, Muchtar E, Gertz M. 2019; New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Rev. [Epub ahead of print]. DOI: 10.1016/j.blre.2019.100636. PMID: 31706583.

13. Gillmore JD, Maurer MS, Falk RH, et al. 2016; Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 133:2404–12. DOI: 10.1161/CIRCULATIONAHA.116.021612. PMID: 27143678.

14. Schönland SO, Hegenbart U, Bochtler T, et al. 2012; Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 119:488–93. DOI: 10.1182/blood-2011-06-358507. PMID: 22106346.

15. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. 2009; Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 114:4957–9. DOI: 10.1182/blood-2009-07-230722. PMID: 19797517.

16. Dispenzieri A, Gertz MA, Kyle RA, et al. 2004; Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 22:3751–7. DOI: 10.1200/JCO.2004.03.029. PMID: 15365071.

17. Kumar S, Dispenzieri A, Lacy MQ, et al. 2012; Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 30:989–95. DOI: 10.1200/JCO.2011.38.5724. PMID: 22331953. PMCID: PMC3675680.

18. Muchtar E, Therneau TM, Larson DR, et al. 2019; Comparative analysis of staging systems in AL amyloidosis. Leukemia. 33:811–4. DOI: 10.1038/s41375-018-0370-z. PMID: 30675009.

19. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. 2019; Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 133:215–23. DOI: 10.1182/blood-2018-06-858951. PMID: 30333122.

20. Vaxman I, Sidiqi MH, Gertz M. 2018; Venetoclax for the treatment of multiple myeloma. Expert Rev Hematol. 11:915–20. DOI: 10.1080/17474086.2018.1548931. PMID: 30428277.

21. Gertz MA, Landau H, Comenzo RL, et al. 2016; First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 34:1097–103. DOI: 10.1200/JCO.2015.63.6530. PMID: 26858336. PMCID: PMC5470113.

22. Edwards CV, Bhutani D, Mapara M, et al. 2019; One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 26:115–6. DOI: 10.1080/13506129.2019.1584892. PMID: 31343323.

23. Richards DB, Cookson LM, Berges AC, et al. 2015; Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 373:1106–14. DOI: 10.1056/NEJMoa1504942. PMID: 26176329.

24. Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. 2019; Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci. 4:438–48. DOI: 10.1016/j.jacbts.2019.02.002. PMID: 31312767. PMCID: PMC6609907.